65.72
5.72%
-3.99
Pre-market:
66.00
0.28
+0.43%
Axsome Therapeutics Inc stock is currently priced at $65.72, with a 24-hour trading volume of 821.35K.
It has seen a -5.72% decreased in the last 24 hours and a -9.40% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $69.55 pivot point. If it approaches the $65.70 support level, significant changes may occur.
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Axsome Therapeutics Inc (AXSM) Revenue 2024
AXSM reported a revenue (TTM) of $270.60 million for the quarter ending December 31, 2023.
Axsome Therapeutics Inc (AXSM) Net Income 2024
AXSM net income (TTM) was -$239.24 million for the quarter ending December 31, 2023, a -27.84% decrease year-over-year.
Axsome Therapeutics Inc (AXSM) Cash Flow 2024
AXSM recorded a free cash flow (TTM) of -$145.66 million for the quarter ending December 31, 2023, a -24.27% decrease year-over-year.
Axsome Therapeutics Inc (AXSM) Earnings per Share 2024
AXSM earnings per share (TTM) was -$5.20 for the quarter ending December 31, 2023, a -13.79% decline year-over-year.
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Jacobson Mark L. | Chief Operating Officer |
Apr 01 '24 |
Sale |
77.24 |
24,662 |
1,904,942 |
0 |
JEFFS ROGER | Director |
Mar 15 '24 |
Option Exercise |
29.91 |
2,347 |
70,199 |
123,103 |
JEFFS ROGER | Director |
Mar 15 '24 |
Sale |
71.61 |
2,347 |
168,062 |
120,756 |
JEFFS ROGER | Director |
Mar 14 '24 |
Option Exercise |
24.01 |
29,976 |
719,787 |
137,732 |
JEFFS ROGER | Director |
Mar 14 '24 |
Sale |
69.70 |
29,976 |
2,089,387 |
120,756 |
Coleman Mark | Director |
Sep 15 '23 |
Option Exercise |
3.67 |
11,016 |
40,429 |
36,113 |
Coleman Mark | Director |
Sep 15 '23 |
Sale |
75.18 |
18,572 |
1,396,189 |
403,856 |
Coleman Mark | Director |
Sep 15 '23 |
Sale |
75.19 |
11,016 |
828,241 |
25,097 |
Axsome Therapeutics Inc Stock (AXSM) Latest News
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
The Motley Fool
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
GlobeNewswire Inc.
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Zacks Investment Research
Analyst Ratings For Axsome Therapeutics
Benzinga
2 Under-the-Radar Growth Stocks to Consider
The Motley Fool
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
GlobeNewswire Inc.
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.
Cap:
|
Volume (24h):